Grifols, S.A. (NASDAQ:GRFS)

CAPS Rating: 3 out of 5

Results 1 - 3 of 3

Recs

0
Member Avatar pagliacci100 (62.62) Submitted: 9/18/2014 3:56:45 PM : Outperform Start Price: $38.58 GRFS Score: -7.45

I fully intend to own this but for how much? is still a mystery

Recs

0
Member Avatar GiantMonster (< 20) Submitted: 4/29/2013 11:37:38 AM : Outperform Start Price: $30.18 GRFS Score: -6.89

strong player in a consolidated market with growing demand

Recs

0
Member Avatar jspirz (< 20) Submitted: 2/26/2013 2:12:45 PM : Outperform Start Price: $28.08 GRFS Score: -5.79

Still realizing their potential after acquiring Talecris. Now a major player in the human plasma protein based therapy's.

Results 1 - 3 of 3

Featured Broker Partners


Advertisement